Literature DB >> 22890763

Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia.

Jonathan Z Li1, Sebastien Gallien, Tri D Do, Jeffrey N Martin, Steven Deeks, Daniel R Kuritzkes, Hiroyu Hatano.   

Abstract

HIV-1 resistance testing was performed in 47 antiretroviral (ARV)-treated subjects with low-level viremia (LLV) of <1,000 copies/ml. The median viral load was 267 copies/ml. In those with ≥2 LLV episodes, 44% accumulated additional resistance mutations. Fewer active ARVs and longer elapsed time were associated with an increased risk of resistance accumulation after controlling for adherence and viral load. Virologic failure followed 16% of LLV time points. Strategies for early intervention after LLV episodes should be further studied.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22890763      PMCID： PMC3486544          DOI： 10.1128/AAC.01217-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy.

Authors:  Gilbert Greub; Alessandro Cozzi-Lepri; Bruno Ledergerber; Schlomo Staszewski; Luc Perrin; Veronica Miller; Patrick Francioli; Hansjakob Furrer; Manuel Battegay; Pietro Vernazza; Enos Bernasconi; Huldrych F Günthard; Bernard Hirschel; Andrew N Phillips; Amalio Telenti
Journal:  AIDS       Date:  2002-09-27       Impact factor: 4.177

2.  Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.

Authors:  Richard E Nettles; Tara L Kieffer; Patty Kwon; Daphne Monie; Yefei Han; Teresa Parsons; Joseph Cofrancesco; Joel E Gallant; Thomas C Quinn; Brooks Jackson; Charles Flexner; Kathryn Carson; Stuart Ray; Deborah Persaud; Robert F Siliciano
Journal:  JAMA       Date:  2005-02-16       Impact factor: 56.272

3.  Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia.

Authors:  Nicola E Mackie; Andrew N Phillips; Steve Kaye; Clare Booth; Anna-Maria Geretti
Journal:  J Infect Dis       Date:  2010-05-01       Impact factor: 5.226

4.  Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus.

Authors:  Nicole H Tobin; Gerald H Learn; Sarah E Holte; Yang Wang; Ann J Melvin; Jennifer L McKernan; Diane M Pawluk; Kathleen M Mohan; Paul F Lewis; James I Mullins; Lisa M Frenkel
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

5.  Improved viral suppression after treatment optimization in HIV-infected patients with persistent low-level viremia.

Authors:  Michael J McConnell; Julian Mier-Mota; Fernando Flor-Parra; Francisco J Martinez-Fernandez; Luis F Lopez-Cortes; Pompeyo Viciana; Felipe Fernandez-Cuenca; Pilar Perez-Romero
Journal:  J Acquir Immune Defic Syndr       Date:  2011-12-15       Impact factor: 3.731

6.  Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy.

Authors:  Babafemi Taiwo; Sebastien Gallien; Evgenia Aga; Heather Ribaudo; Richard Haubrich; Daniel R Kuritzkes; Joseph J Eron
Journal:  J Infect Dis       Date:  2011-08-15       Impact factor: 5.226

7.  Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia.

Authors:  Sébastien Gallien; Constance Delaugerre; Isabelle Charreau; Joséphine Braun; Thomas Boulet; Aurélie Barrail-Tran; Nathalie de Castro; Jean-Michel Molina; Daniel R Kuritzkes
Journal:  AIDS       Date:  2011-03-13       Impact factor: 4.177

8.  Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.

Authors:  Anna M Geretti; Colette Smith; Annette Haberl; Ana Garcia-Diaz; Gaia Nebbia; Margaret Johnson; Andrew Phillips; Schlomo Staszewski
Journal:  Antivir Ther       Date:  2008

9.  Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy.

Authors:  Richard E Nettles; Tara L Kieffer; Rachel P Simmons; Joseph Cofrancesco; Richard D Moore; Joel E Gallant; Deborah Persaud; Robert F Siliciano
Journal:  Clin Infect Dis       Date:  2004-09-01       Impact factor: 9.079

Review 10.  Low-level viremia in HIV-1 infection: consequences and implications for switching to a new regimen.

Authors:  Calvin Cohen
Journal:  HIV Clin Trials       Date:  2009 Mar-Apr
View more
  19 in total

1.  HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure.

Authors:  Luke C Swenson; Jeong Eun Min; Conan K Woods; Eric Cai; Jonathan Z Li; Julio S G Montaner; P Richard Harrigan; Alejandro Gonzalez-Serna
Journal:  AIDS       Date:  2014-05-15       Impact factor: 4.177

2.  Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases.

Authors:  Timothy J Henrich; Emily Hanhauser; Francisco M Marty; Michael N Sirignano; Sheila Keating; Tzong-Hae Lee; Yvonne P Robles; Benjamin T Davis; Jonathan Z Li; Andrea Heisey; Alison L Hill; Michael P Busch; Philippe Armand; Robert J Soiffer; Marcus Altfeld; Daniel R Kuritzkes
Journal:  Ann Intern Med       Date:  2014-09-02       Impact factor: 25.391

3.  Low-level viremia and virologic failure in persons with HIV infection treated with antiretroviral therapy.

Authors:  Julia Fleming; W Christopher Mathews; Richard M Rutstein; Judith Aberg; Charurut Somboonwit; Laura W Cheever; Stephen A Berry; Kelly A Gebo; Richard D Moore
Journal:  AIDS       Date:  2019-11-01       Impact factor: 4.177

4.  The significance of low-level viraemia in diverse settings: analysis of the Treat Asia HIV Observational Database (TAHOD) and the Australian HIV Observational Database (AHOD).

Authors:  R Kanapathipillai; H McManus; D D Cuong; O T Ng; N V Kinh; M Giles; T Read; I Woolley
Journal:  HIV Med       Date:  2014-01-26       Impact factor: 3.180

5.  Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals.

Authors:  A Gonzalez-Serna; J E Min; C Woods; D Chan; V D Lima; J S G Montaner; P R Harrigan; L C Swenson
Journal:  Clin Infect Dis       Date:  2014-01-14       Impact factor: 9.079

6.  CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy.

Authors:  Babafemi Taiwo; Peter W Hunt; Rajesh T Gandhi; Andrew Ellingson; Matthew McKenna; Jeffrey M Jacobson; Barbara Gripshover; Ronald J Bosch
Journal:  J Acquir Immune Defic Syndr       Date:  2013-05-01       Impact factor: 3.731

7.  Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients.

Authors:  Patrick Ryscavage; Sean Kelly; Jonathan Z Li; P Richard Harrigan; Babafemi Taiwo
Journal:  Antimicrob Agents Chemother       Date:  2014-04-14       Impact factor: 5.191

8.  Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia.

Authors:  Saran Vardhanabhuti; Babafemi Taiwo; Daniel R Kuritzkes; Joseph J Eron; Ronald J Bosch
Journal:  Antivir Ther       Date:  2014-04-04

9.  Antiretroviral regimen and suboptimal medication adherence are associated with low-level human immunodeficiency virus viremia.

Authors:  Christina Konstantopoulos; Heather Ribaudo; Kathleen Ragland; David R Bangsberg; Jonathan Z Li
Journal:  Open Forum Infect Dis       Date:  2015-01-14       Impact factor: 3.835

Review 10.  HIV Replication at Low Copy Number and its Correlation with the HIV Reservoir: A Clinical Perspective.

Authors:  Loredana Sarmati; Gabriella D'Ettorre; Saverio Giuseppe Parisi; Massimo Andreoni
Journal:  Curr HIV Res       Date:  2015       Impact factor: 1.581
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.